Company Filing History:

18 out of 613

Sankyo Company, Limited

patents

4 out of 441

Daiichi Sankyo Company, Limited

patents

3 out of 11

Mitsubishi-Kagaku Foods Corporation

patents

where one patent can have more than one assignee

Years Active: 1977-2015

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8957201 - Oligonucleotide analogues and methods utilizing the same (2015-02-17),

2. 7816333 - Oligonucleotide analogues and methods utilizing the same (2010-10-19),

3. 7335765 - Nucleoside and oligonucleotide analogues (2008-02-26),

4. 7314923 - Nucleoside and oligonucleotide analogues (2008-01-01),

5. 7157442 - Antibacterial compound (2007-01-02),

6. 6472384 - Antimicrobial compounds (2002-10-29),

7. 5807837 - Composition and method for the treatment or prophylaxis of viral (1998-09-15),

8. 5760042 - Griseolic acid derivatives, their preparation and their use (1998-06-02),

9. 5691319 - Pyrimidine nucleoside derivatives having anti-tumor activity, their (1997-11-25),

10. 5674856 - Modified oligodeoxyribonucleoditides (1997-10-07),

11. 5616600 - Griseolic acid compounds and their use as a phosphodiesterase inhibitor (1997-04-01),

12. 5556975 - Griseolic acid derivatives (1996-09-17),

13. 5532369 - Intermediates for griseolic acid derivatives (1996-07-02),

14. 5498819 - Griseolic acid derivatives, their preparation and their use (1996-03-12),

15. 5391564 - Rhizoxin derivatives and their use as anti-tumor agents (1995-02-21),

Title: Masakatsu Kaneko: Innovator in Oligonucleotide Technology

Introduction

Masakatsu Kaneko is a notable inventor based in Tokyo, Japan, recognized for his contributions to the field of oligonucleotide technology. With a total of 22 patents to his name, Kaneko has been instrumental in advancing methods for the prevention and treatment of diseases through innovative pharmaceutical applications.

Latest Patents

Among Kaneko's latest patents is a significant innovation involving oligonucleotide analogues and methods utilizing them for the prevention or treatment of diseases in mammals. This method entails administering a pharmaceutically effective amount of oligonucleotide analogue that comprises two or more nucleoside units, where at least one unit follows a specific structural formula. This research is groundbreaking, paving the way for improved therapeutic strategies through the pharmacologically useful antisense or antigene activity of these oligonucleotide analogues.

Career Highlights

Throughout his career, Kaneko has worked with prestigious pharmaceutical companies, notably Sankyo Company, Limited and Daiichi Sankyo Company, Limited. His time at these organizations has allowed him to apply his innovative ideas within collaborative environments aimed at addressing substantial health challenges through molecular advancements.

Collaborations

Kaneko has collaborated with fellow researchers, including Misako Kimura and Yoshinobu Murofushi. These partnerships have been pivotal in the development of his inventions, showcasing the importance of teamwork in achieving breakthroughs in pharmaceutical research.

Conclusion

Masakatsu Kaneko's contributions to the field of oligonucleotide technology have made significant strides towards innovative treatments for various diseases. His ongoing commitment to research and collaboration continues to inspire future generations of inventors and scientists in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com